Cartherics Lab
A discovery-to-clinic engine for cell therapies
Cartherics’ purpose-built research and manufacturing facility in Melbourne provides the integrated infrastructure needed to develop, manufacture and translate cell therapies from discovery to the clinic.
The facility houses PC2 laboratories, dedicated tissue culture laboratories, GMP-ready clean rooms and biobanking capabilities, supporting both research and clinical-grade manufacturing. Designed to enable scalable production of Cartherics’ induced pluripotent stem cell (iPSC)-derived CAR natural killer (CAR-iNK) cell therapies, the facility underpins the company’s end-to-end development model, from cell line engineering and process development through to manufacturing for clinical trials.
By combining research, process development and manufacturing under one roof, Cartherics has established a discovery-to-clinic engine that accelerates innovation, strengthens Australia’s sovereign cell therapy capability and positions the company to efficiently advance multiple allogeneic cell therapy programs into the clinic.
We’re proud of the team, platform and capability that we’ve built at Cartherics. We have developed the ability to go from starting stem cells all the way through to the manufacture of gene-edited natural killer cells for clinical trials, all within our own facility. This gives us greater control over the development process and the ability to efficiently advance our pipeline towards clinical milestones.
Dr Ian Nisbet PhD
CEO of Cartherics
